Shares of Gilead Sciences (NASDAQ:GILD) dropped 2.8% Monday morning after reports emerged that U.S. Health and Human Services ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the group of viruses to eliminate them as a public ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members of a key advisory panel that ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...